Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines

blonca9
Nov 26, 2024
1 min read

Founder and CEO Seulki Lee describes his training in science, part of which was working on GLP-1s years ago, and the founding of the company. He walks us through D&D's pipeline, including oral GLP medicines that have been licensed to Metsera in the United States for development.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight